
|Videos|August 24, 2022
Patient Selection for Atopic Dermatitis Therapies
Elizabeth A. Swanson, MD, provide insight on identifying the appropriate patients for various therapeutic regimens in atopic dermatitis.
Advertisement
Episodes in this series

Advertisement
Related to this article

At ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.

US preterm birth rate held at 10.4%, earning a fifth straight D+ from March of Dimes; maternal deaths fell, but racial disparities persist.

In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.

Data presented at NSGC 2026 tie maternal autoantibody combinations to a non-genetic autism subtype with high recurrence risk in later-born siblings.

Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.

Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.

In STEP Young, semaglutide cut BMI 13.5% at 68 weeks vs a 2.7% rise with placebo in children aged 6 to <12 years with obesity.
Advertisement
Advertisement






